N-{(2S,3R)-4,4-Difluoro-1-(2-Hydroxy-2-Methylpropanoyl)-2-[(2,3',5'-Trifluoro[1,1'-Biphenyl]-3-Yl)Methyl]Pyrrolidin-3-Yl}Ethanesulfonamide

4 trials Orphan designation

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

0 Recruiting

4 Completed trials

1 Sponsors

14 Countries

Phase III

Phase II/III

Phase I (Other)

Phase III: 2 Phase II/III: 1 Phase I (Other): 1

Oversight events:

1 serious breach across 1 trial

View oversight register →

Indications tested

Sponsors using this IMP

Takeda Development Center Americas Inc. 4

All trials

4 total

A Trial to Evaluate the Long-term Safety and Tolerability of TAK-861 Ended

2023-508462-15-00 Phase II/III 11 countries Takeda Development Center Americas Inc.
Open-label single dose trial to evaluate pharmacokinetics, safety, and acceptability/palatability of oveporexton in children from 6 years to… Ended

2025-522034-31-00 Phase I (Other) 1 country Takeda Development Center Americas Inc.
A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy Ended

2024-511998-30-00 Phase III 11 countries Takeda Development Center Americas Inc.
A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy Ended

2023-508465-32-00 Phase III 6 countries Takeda Development Center Americas Inc.

Showing 1–4 of 4 trials

← All drugs A–Z